[Federal Register Volume 70, Number 236 (Friday, December 9, 2005)]
[Rules and Regulations]
[Page 73137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-23811]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524


Ophthalmic and Topical Dosage Form New Animal Drugs; Miconazole 
Nitrate Cream; Miconazole Nitrate Lotion; Miconazole Nitrate Spray

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by First Priority, Inc. The ANADA provides 
for topical use of miconazole nitrate as a spray or lotion on dogs and 
cats for the treatment of certain fungal infections.

DATES: This rule is effective December 9, 2005.

FOR FURTHER INFORMATION CONTACT: Linda M. Wilmot, Center for Veterinary 
Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-827-1069, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: First Priority, Inc., 1585 Todd Farm Dr., 
Elgin, IL 60123, filed ANADA 200-362 for PRICONAZOLE (miconazole 
nitrate) Lotion 1% and PRICONAZOLE (miconazole nitrate) Spray 1% for 
topical use on dogs and cats for the treatment of certain fungal 
infections. First Priority's PRICONAZOLE Lotion 1% and PRICONAZOLE 
Spray 1% are approved as generic copies of Schering-Plough Animal 
Health Corp.'s CONOFITE Lotion 1% and Spray 1%, approved under NADA 95-
184. The ANADA is approved as of November 14, 2005, and 21 CFR 524.1443 
is amended to reflect the approval. The basis of approval is discussed 
in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    FDA has determined under 21 CFR 25.33(a)(1) that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 524

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is 
amended as follows:

PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 524 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec.  524.1443  [Amended]

0
2. Section 524.1443 is amended in paragraph (b) by removing ``No. 
051259'' and by adding in its place ``Nos. 051259 and 058829''.

    Dated: November 30, 2005.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 05-23811 Filed 12-8-05; 8:45 am]
BILLING CODE 4160-01-S